Centinel Spine Announces prodisc C Clinical Trials

Centinel Spine announced Investigational Device Exemption approval from FDA to initiate a two-level clinical trial with prodisc® C Vivo and prodisc C SK anterior cervical total disc replacement devices (TDRs).

The two-level prospective, randomized study will evaluate the devices at multiple sites throughout the U.S., comparing them to an...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us